DENND2D通过调控PARP1对非小细胞肺癌细胞系H1299中顺铂细胞毒性的影响

doi:10.3969/j.issn.1004-616x.2013.02.002

Abstract

Abstract:

OBJECTIVE: To investigate the effect of DENN/MADD domain containing 2D (DENND2D) gene on the cytotoxity of cisplatinum in non-small cell lung cancer cell line H1299 and explore the mechanism preliminarily. METHODS：DENND2D gene was transient & stably transfected into H1299 cells. CCK-8 assay was used to test the cell counts of DENND2D transfected H1299 cells treated with various concentrations of cisplatinum and IC50 results were attained. PARP1 protein expression was evaluated by western blot. DENND2D over-expressed H1299 cells were treated with cisplatinum for 0，1，2，4 and 8 h. The PAR expressions were measured by Western blot. RESULTS：IC50 was decreased in DENND2D over-expressed group compared to vector group. PARP1 and PAR were down-regulated in DENND2D over-expressed H1299 cells. With the prolonged platinum treatment time，the expression of PAR was down-regulated in DENND2D group whereas it was opposite in the vector group. CONCLUSION：DENND2D may enhanced the cytotoxicity of cisplatinum in H1299 cells by down regulating PARP1.

Key words: DENND2D, PARP1, cisplatinum, non-small cell lung cancer, cytotoxicity

LING Bing，FENG Lin，CHENG Shu-jun. Effect of DENND2Don the cisplatinum cytotoxicity in H1299 cells by regulating PARP1[J]. Carcinogenesis, Teratogenesis & Mutagenesis, doi: 10.3969/j.issn.1004-616x.2013.02.002.

References

[1] Tiseo M，Franciosi V，Grossi F，et al. Adjuvant chemotherapy for non-small cell lung cancer：ready for clinical practice?[J]. Eur J Cancer，2006，42 (1)：8-16.

[2] Perez RP. Cellular and molecular determinants of cisplatin resistance[J]. Eur J Cancer，1998，34 (10)：1535-1542.

[3] Baruah H，Barry CG，Bierbach U. Platinum-intercalator conjugates： from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation[J]. Curr Top Med Chem，2004，4 (15)：1537-1549.

[4] Hassa PO，Hottiger MO. The diverse biological roles of mammalian PARPS，a small but powerful family of poly-ADP-ribose polymerases[J]. Front Biosci，2008，13：3046-3082.

[5] Hassa PO. The molecular“Jekyll and Hyde”duality of PARP1 in cell death and cell survival[J]. Front Biosci，2009，14：72-111.

[6] Sun W，Zhang K，Zhang X，et al. Identification of differentially expressed genes in human lung squamous cell carcinoma using suppression subtractive hybridization[J]. Cancer Lett，2004， 212 (1)：83-93.

[7] Ling B，Zheng H，Fu G，et al. Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D[J]. Lung Cancer，2013，79 (2)：104-110.

[8] Yoshimura S，Gerondopoulos A，Linford A，et al. Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors[J]. J Cell Biol，2010，191 (2)：367-381.

[9] Lee ES，Son DS，Kim SH，et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression[J]. Clin Cancer Res，2008，14 (22)：7397-7404.

[10] Ziegler M，Oei SL. A cellular survival switch：poly (ADP-ribosyl) ation stimulates DNA repair and silences transcription [J]. Bioessays，2001，23 (6)：543-548.

[11] Andriani F，Perego P，Carenini N，et al. Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer[J]. Neoplasia，2006，8 (1)：9-17.

[12] Deng WG，Wu G，Ueda K，et al. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1[J]. Cancer Gene Ther，2008，15 (1)：29-39.

[13] Lai SL，Perng RP，Hwang J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells[J]. J Biomed Sci，2000，7 (1)：64-70.

[14] Nakagawa T，Inoue Y，Kodama H，et al. Expression of copper- transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts[J]. Oncol Rep，2008，20 (2)：265-270.

[15] Nishi M，Abe Y，Fujimori S，et al. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo[J]. Oncol Rep，2005， 14 (2)：421-424.

[16] Hassa PO，Haenni SS，Elser M，et al. Nuclear ADP-ribosylation reactions in mammalian cells：where are we today and where are we going?[J]. Microbiol Mol Biol Rev，2006，70 (3)：789-829.

[17] Stordal B，Pavlakis N，Davey R. A systematic review of platinum and taxane resistance from bench to clinic：an inverse relationship[J]. Cancer Treat Rev，2007，33 (8)：688-703.

Effect of DENND2Don the cisplatinum cytotoxicity in H1299 cells by regulating PARP1

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 12

Recommended Articles

Metrics

Comments

[1]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[2]	WANG Xikai, MENG Qinghe, GAO Yanlu. miR-223-3p negatively regulated ECT2 to induce apoptosis in non-small cell lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 187-192.
[3]	LIU Xiaoxia, LI Weixia, SU Zhenjun, JIA Jinhai, DUAN Xiaohui, LI Zhijia, HE Xiaolei, L Linlin, LIU Rui, WANG Yunxiao. Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 350-354.
[4]	YING Wei, WANG Xingyuan, JIANG Bo, ZHOU Wei. Association between polymorphisms in the miR-146a and susceptibility to non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 222-226.
[5]	ZHU Jiawei, HU Xiao, WANG Xijun, WANG Yaru, FENG Lin, XIAO Ting. Clinical significance of Skp1 protein expression in non-small cell lung cancer tissues and peripheral blood [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 89-95.
[6]	ZHANG Jing, TENG Yu, ZHAO Xiaoting, JIANG Mei, YUE Wentao. Effects of the inhibitor of Wnt production 2 on cell migration and invasion in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 245-250.
[7]	SONG Jie, LI Ping, YU Xuexin, FENG Lin, GAO Yanning, XIAO Ting. Expression of Syntenin in non-small cell lung cancer tissues and its relationship with overall survival of patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(2): 102-105.
[8]	ZHAI Xiaoran, JIANG Mei, ZHAO Xiaoting, GU Meng, YUE Wentao. Clinical significance of PFTK1 expression in human non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(3): 231-235.
[9]	WU Juan, DU Yun, WANG Heng, WU Jianing, ZHAO Yinhuan, WANG Rui, ZHANG Yan, JI Xiaokun. Detection of EGFR gene mutation in non-small cell lung cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 27-31.
[10]	CHEN Ying，LI Ying，MA Ai-cui，XU Li，PAN Qi，LIU Xiang-yun，ZHOU Li，SUN Zu-yue. Comparetive study of different solvent toxicity on CHL cells in chromosome aberration test [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(5): 373-376.
[11]	WANG Feng-yun, ZHANG Yan-qiao*, LUO Ming, WU Yun, LI Peng, LI Zhi-wei, SUN Wei. The expressions of p-Stat3 , VEGF-C and MMP-2 in non-small cell lung cancer and their relationship with lymph node metastasis [J]. , 2011, 23(2): 107-110.
[12]	QIU Rong1, SIMA Jun2, SHEN Xiang-di1, ZHOU Ren3. Effect of Hypoxia on Inducing Apoptosis in Non-small Cell Lung Cancer A549 and Expression of Survivin Gene [J]. , 2009, 21(1): 24-026.